Medicine and Dentistry
Uveitis
100%
Pancreas Adenocarcinoma
90%
Asthma
80%
Disease
67%
Steroid Treatment
56%
Macular Edema
56%
Pancreas Cancer
52%
Papillomavirus Infection
51%
Fluocinolone Acetonide
47%
Arm
45%
Visual Acuity
45%
Systemic Therapy
44%
Placebo
43%
Human Immunodeficiency Virus
41%
Randomized Clinical Trial
39%
Hazard Ratio
37%
Overall Survival
37%
Wart Virus
35%
Infection
34%
Pancreas Tumor
33%
Cohort Analysis
29%
Biological Marker
26%
Neoplasm
25%
Low Drug Dose
25%
Tumor Vaccine
24%
Gemcitabine
24%
Chronic Obstructive Pulmonary Disease
24%
Stereotactic Body Radiation Therapy
24%
Dexamethasone
24%
Quality of Life
24%
Implant
24%
Optical Coherence Tomography
23%
Symptom
22%
Cyclophosphamide
21%
Granulocyte Macrophage Colony Stimulating Factor
20%
Cataract Surgery
19%
Best Corrected Visual Acuity
19%
Cerebral Hemorrhage
18%
Methylation
18%
Azacitidine
18%
Immunotherapy
18%
Phase II Trials
17%
Alteplase
17%
Clinical Trial
17%
Adolescent
17%
Evacuation
16%
Nivolumab
16%
National Eye Institute Visual Function Questionnaire
16%
Minimally Invasive Surgery
16%
Ipilimumab
16%
Keyphrases
Uveitis
65%
Confidence Interval
51%
Oral Human Papillomavirus
51%
Steroid Treatment
41%
Allogeneic
40%
Panuveitis
40%
Overall Survival
39%
Asthma
39%
Treatment Trials
38%
Risk Factors
36%
Pancreatic Adenocarcinoma
36%
Uveitic Macular Edema
35%
Visual Acuity
35%
Systemic Therapy
33%
Therapeutic Vaccine
33%
Papillomavirus Infections
30%
Macular Edema
30%
Phase II Study
30%
Fluocinolone Acetonide Implant
29%
Granulocyte Colony-stimulating Factor (G-CSF)
28%
Pancreatic Ductal Adenocarcinoma
28%
Pancreatic Cancer
27%
Gemcitabine
24%
Step-down
24%
HPV16
24%
Randomized Clinical Trial
21%
Metastatic Pancreatic Ductal Adenocarcinoma
21%
Pancreatic Tumor Cells
21%
Cataract Surgery
20%
High Risk
19%
Phase II Trial
18%
Hazard Ratio
18%
Best-corrected Visual Acuity
17%
VFQ-25
16%
Pancreatic Tumor
16%
Neoadjuvant
16%
Systemic Anti-inflammatory Therapy
16%
Nivolumab
16%
Pancreas
16%
Long-acting beta-agonists
16%
Ipilimumab
16%
Seropositivity
16%
Obesity
16%
Stereotactic Body Radiation Therapy
16%
Disease-free Survival
15%
Asthma Symptoms
15%
Clinical Trials
14%
Adjusted Hazard Ratio
14%
Methotrexate
14%
Uveitic
14%
Pharmacology, Toxicology and Pharmaceutical Science
Asthma
74%
Pancreas Adenocarcinoma
70%
Disease
57%
Uveitis
44%
Pancreas Cancer
43%
Randomized Clinical Trial
35%
Neoplasm
34%
Overall Survival
33%
Placebo
31%
Macular Edema
31%
Chemotherapy
29%
Malignant Neoplasm
27%
Pancreas Tumor
27%
Tumor Vaccine
24%
Dexamethasone
24%
Human Papillomavirus
24%
Papillomavirus Infection
22%
Infection
21%
Granulocyte Macrophage Colony Stimulating Factor
20%
HIV
18%
Phase II Trials
18%
Multiple Sclerosis
16%
Gemcitabine
16%
Ipilimumab
16%
Chronic Obstructive Lung Disease
16%
Beta Adrenergic Receptor Stimulating Agent
16%
Anti-Inflammatory Drug
16%
Chemoradiation Therapy
16%
Progression Free Survival
15%
Immunotherapy
14%
Methotrexate
14%
Steroid Treatment
12%
Ranibizumab
12%
Fluorouracil
11%
Clinical Trial
11%
Mesothelin
11%
Azacitidine
11%
Vitamin D
10%
Fluocinolone Acetonide
10%
Methacholine
10%
Symptom
10%
Respiratory Tract Inflammation
9%
Cholecalciferol
9%
Biological Marker
9%
Histone Deacetylase Inhibitor
8%
Antizyme
8%
Isoflavone
8%
Cytokine
8%
Triamcinolone
8%
Neutropenia
8%
